Alnylam Pharmaceuticals ALNY NASDAQ · Healthcare · United States
$165.04 +5.36% +$8.39
Summary
74 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 54 USD is left as net profit.
- Revenue grew by 53% a year over the last 3 years.
- It earns 50 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $1.75B against $1.26B.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 7.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 50% a year over 5 years. Over the last 3 years it grew by 53% a year. For the next fiscal year analysts expect revenue to grow by 47%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 23 USD
- Research and development 31 USD
- Sales and administration 27 USD
- Taxes and other -35 USD
- Net profit 54 USD
Net profit, industry median (Biotechnology) -11 USD
Out of every 100 USD of revenue, 54 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.5 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 37
- Hold 14
- Sell 1
Today's price within the analysts' price targets
The average target of $332.46 is 101% above today's price. 71% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- AMVUTTRA 62%
- Net revenues from collaborations 15%
- GIVLAARI 8.3%
- OXLUMO 5.2%
- Royalty revenue 4.7%
- Other 4.7%
By region
- UNITED STATES 75%
- Europe 18%
- Non-US Or Europe 7.6%
AMVUTTRA brings in 62% of revenue. GIVLAARI grew fastest, by 19% a year.
Segments in detail